摘要
乳酸-乙醇酸共聚物[poly(lactide-co-gly-colide),PLGA]是一种前景良好的可降解合成高分子材料,作为缓释给药系统的基体材料被广泛研究。这主要基于其优异的生物相容性、可调控的生物降解性,以及已被欧美药监局批准等优点。微球缓释给药可延长药物的半衰期,增加临床治疗效果,在医药行业和生物材料领域备受推崇。药物的稳定性和释放动力学特征是微球研究中的两个关键问题,也主导着临床治疗的效果。围绕最近两年关于PLGA微球所载药物的稳定性及释放动力学的研究报道,结合本课题组在PLGA微球加载骨生长因子(人重组骨形态发生蛋白rhBMP-2及其相关多肽)方面的工作作一个综述。同时,总结了现有国内外主要的PLGA微球产品,展望了微球载药体系的前景。
Poly(lactide-co-glycolide,PLGA) is a kind of degradable synthetic polymer which has been intensively studied as the matrix of controlled release systems.The good prospect is mainly based on its good biocompatibility,controlled biodegradability and the fact that it has been accepted for clinical applications by US/EU FDA.The microsphere controlled release systems are able to extend drug's half-life and enhance therapeutic efficacy,so they are preferentially selected in drug delivery and biomaterial domains.The stability and release dynamic of drugs are two Key issues that decide the therapeutic efficacy.This review focuses on the recent studies about the drug stability and drug release dynamic,associating our researches about the PLGA microsphere loaded with rhBMP-2 and the rhBMP-2 derived peptides.The available PLGA controlled release products are listed and the expected future is proposed.
出处
《功能材料》
EI
CAS
CSCD
北大核心
2011年第S4期591-595,共5页
Journal of Functional Materials
基金
国家自然科学基金资助项目(51072090
51061130554)
